SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: The therapeutic utility of such an approach was recently demonstrated for Dravet syndrome, where CRISPRa was used to upregulate the expression of the WT Scn1a allele by ~ 50%, and improved the epileptic phenotype [42].